BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nexatoclax readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nexatoclax\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06207123-2930@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Nexatoclax: Phase 1/2 readout est. (NCT06207123)
DESCRIPTION:Nexatoclax\, phase 1/2.\nStudy: A Study to Investigate LP-118\,
  Ponatinib\, Vincristine and Dexamethasone in Relapsed/Refractory Acute Ly
 mphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)\nEstimated prim
 ary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nexatoclax#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06207123
URL:https://assetmemo.bio/drug/nexatoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04771572-2930@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nexatoclax: Phase 1 readout est. (NCT04771572)
DESCRIPTION:Nexatoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: Study of
  Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL
 \, SLL\, MDS\, MDS/MPN\, AML\, CMML-2\, MPN-BP\, ALL\, MF\, NHL\, RT\, MM 
 or T-PLL.\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nexatoclax#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04771572
URL:https://assetmemo.bio/drug/nexatoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614022-2930@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Nexatoclax: Phase 1 readout est. (NCT07614022)
DESCRIPTION:Nexatoclax\, phase 1.\nStudy: A Study of LP-118 In Combination 
 With Ponatinib\, Dexamethasone And Blinatumomab For Adults With Newly-Diag
 nosed\, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)\nEstimated p
 rimary completion: March 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nexatoclax#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07614022
URL:https://assetmemo.bio/drug/nexatoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
